- Home
- MGNX vs MYPS Comparison
MGNX vs MYPS Comparison
Compare MGNX & MYPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- MYPS
- Stock Information
- Founded
- MGNX 2000
- MYPS 2011
- Country
- MGNX United States
- MYPS United States
- Employees
- MGNX N/A
- MYPS N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- MYPS EDP Services
- Sector
- MGNX Health Care
- MYPS Technology
- Exchange
- MGNX Nasdaq
- MYPS Nasdaq
- Market Cap
- MGNX 257.3M
- MYPS 249.4M
- IPO Year
- MGNX 2013
- MYPS N/A
- Fundamental
- Price
- MGNX $3.23
- MYPS $1.91
- Analyst Decision
- MGNX Hold
- MYPS Hold
- Analyst Count
- MGNX 10
- MYPS 5
- Target Price
- MGNX $7.17
- MYPS $3.17
- AVG Volume (30 Days)
- MGNX 465.7K
- MYPS 262.2K
- Earning Date
- MGNX 11-05-2024
- MYPS 11-04-2024
- Dividend Yield
- MGNX N/A
- MYPS N/A
- EPS Growth
- MGNX N/A
- MYPS N/A
- EPS
- MGNX N/A
- MYPS N/A
- Revenue
- MGNX $141,329,000.00
- MYPS $298,759,000.00
- Revenue This Year
- MGNX $174.73
- MYPS N/A
- Revenue Next Year
- MGNX N/A
- MYPS N/A
- P/E Ratio
- MGNX N/A
- MYPS N/A
- Revenue Growth
- MGNX 16.68
- MYPS N/A
- 52 Week Low
- MGNX $2.95
- MYPS $1.20
- 52 Week High
- MGNX $21.88
- MYPS $3.04
- Technical
- Relative Strength Index (RSI)
- MGNX 42.79
- MYPS 47.81
- Support Level
- MGNX $3.10
- MYPS $2.06
- Resistance Level
- MGNX $3.30
- MYPS $2.02
- Average True Range (ATR)
- MGNX 0.19
- MYPS 0.11
- MACD
- MGNX 0.00
- MYPS -0.04
- Stochastic Oscillator
- MGNX 25.45
- MYPS 7.32
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About MYPS PLAYSTUDIOS Inc.
PLAYSTUDIOS Inc is engaged in gaming and related business. The Company develops and operates online and mobile social gaming applications (games or game), many of which incorporate a loyalty program offering real world rewards provided by a collection of awards partners. The Company's games are free-to-play and available via the Apple App Store, Google Play Store, Amazon Appstore, and Facebook (collectively, platforms or platform operators). The Company creates games based on its own original content as well as third-party licensed brands. The Company generates revenue through the in-game sales of virtual currency and through advertising. The company has one operating segment with one business activity, developing and monetizing social games.